AD_____

GRANT NUMBER DAMD17-96-1-6051

TITLE: Transgenic Mouse Model to Study the Role of EGF Receptor in Breast Cancer

PRINCIPAL INVESTIGATOR: William S. Chen, Ph.D.

CONTRACTING ORGANIZATION: University of Illinois
                          Chicago, Illinois 60612-7205

REPORT DATE: September 1998

TYPE OF REPORT: Annual

PREPARED FOR: Commanding General
                U.S. Army Medical Research and Materiel Command
                Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
                        Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY (Leave blank)	2. REPORT DATE September 1998	3. REPORT TYPE AND DATES COVERED Annual (19 Aug 97 - 18 Aug 98)

4. TITLE AND SUBTITLE
Transgenic Mouse Model to Study the Role of EGF Receptor in Breast Cancer

5. FUNDING NUMBERS
DAMD17-96-1-6051

6. AUTHOR(S)
William S. Chen, Ph.D.

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)
University of Illinois
Chicago, Illinois 60612-7205

8. PERFORMING ORGANIZATION REPORT NUMBER

9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES)
U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

10. SPONSORING/MONITORING AGENCY REPORT NUMBER

19981210 103

11. SUPPLEMENTARY NOTES

12a. DISTRIBUTION / AVAILABILITY STATEMENT

Approved for public release; distribution unlimited

12b. DISTRIBUTION CODE

13. ABSTRACT (Maximum 200

Epidermal growth factor (EGF) receptor is expressed in many normal tissues, including mammary epithelium. Overexpression or mutation of the EGF receptor causes neoplastic transformation in many cell types. Several studies have implicated the EGF receptor as a good prognostic marker in breast cancer, but its role in the etiology and progression of this malignancy is still under dispute. We propose to utilize a genetic approach to investigate this issue, by developing transgenic mice in which the EGF receptor gene in the mammary gland will be inactivated at the onset of first lactation. The construct for gene targeting was made. After introducing the construct in ES cells by electroporation and G418 selection, we have several positive clones for ES cell injection and chimeric mice from some of the positive clones. We hope to generate the transgenic mouse model next year so that we will be able to study the question whether the EGF receptor plays a functional role in the etiology and progression of mammary carcinoma. The answer to this question would indicate the feasibility of using the EGF receptor as a target in breast cancer therapy.

14. SUBJECT TERMS Breast Cancer

15. NUMBER OF PAGES
14

16. PRICE CODE

17. SECURITY CLASSIFICATION OF REPORT	18. SECURITY CLASSIFICATION OF THIS PAGE	19. SECURITY CLASSIFICATION OF ABSTRACT	20. LIMITATION OF ABSTRACT
Unclassified	Unclassified	Unclassified	Unlimited

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)
Prescribed by ANSI Std. Z39-18

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

_____ Where copyrighted material is quoted, permission has been obtained to use such material.

_____ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

_____ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

W.S.C In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

_____ For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

W.S.C In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

W.S.C In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

W.S.C In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

_____ 9-17-98

PI - Signature   Date

Table of Contests

Introduction

  Breast cancer has been the leading cause of death among non-smoking women and thus has been the focus of intensive research. For the last decade or so, many researchers have concentrated on understanding the molecular basis of breast cancer. Since the epithelial cells of the breast are regulated by a variety of hormones and growth factors, it appears that abnormal hormonal milieu might be one of the critical factors in the development of breast cancer. EGF (epidermal growth factor) is a growth-stimulating factors and act as an autocrine and paracrine growth factor. The expression of both EGF and is positively regulated by estrogen and progesterone receptors [1].

  EGF binds to EGF receptor and both epithelial and stromal cells of breast carcinoma express EGF receptor. The EGF receptor is a 170 kDa transmembrane glycoprotein, which belong to the tyrosine kinase receptor family. The role of the EGF receptor in breast cancer has been studied in great detail over the last decade, but it still remains under debate [2]. More than 10,000 breast cancer patients have been assayed for EGF receptor [2]. The expression of EGF receptors on normal breast epithelial cells is low and elevated expression of EGF receptors occurs in about 40% of primary breast cancers. There is a clear reverse relationship between EGF receptor expression and estrogen receptor expression, as well as between the expression of EGF receptor and progesterone receptor [3]. High levels of EGF receptor are associated with poor tumor differentiation, high tumor grade, aneuploidy and high rate of cell proliferation [4]. There is still no consensus, however, on the significance of EGF receptor in breast cancer prognosis or its correlation with the relapse-free survival and overall survival [5,6]. In node-positive patients, the EGF receptor appears to be a good prognostic marker, but in the node-negative patients, the EGF receptor does not appear to have a prognostic value [7,8].

  EGF receptor, is detected in a large variety of tissues with the exception of hemopoietic cells. Overexpression of either the ligand of the EGF receptor or the receptor leads to the transformed phenotype in many different cell types [9-15].

  The development of the transgenic mouse and gene knockout techniques provides an exceptional opportunity to elucidate the role of the EGF receptor signal pathway in mammary gland cancer [16]. Mouse models have already proven to be useful in mammary gland cancer studies. Thus, overexpression of the ligand of EGF receptor in the mammary gland of transgenic mice under the control of a strong MMTV (mouse mammary tumor virus) promoter or a matollothionein promoter results in a much higher rate of mammary neoplasia [17-19]. Neoplastic transformation of mammary glands in transgenic mice was also observed when c-myc was overexpressed from the MMTV or WAP (whey acidic protein) promoter [20,21].

  The role of the EGF receptor in mammary physiology has been indicated by the analysis of a mutant mouse strain, waved-2 [22]. This strain contains a single nucleotide alteration of the EGF receptor gene at position 743, resulting in a valine to glycine substitution in a highly conserved region of the EGF receptor tyrosine kinase domain. The mutant EGF receptor lacks the high

affinity ligand binding and the rate of ligand-dependent internalization is slower than with the wild-type EGF receptor. The phenotype of the waved-2 mouse includes a smaller size of the mammary gland with a reduction of milk in the duct and a less pronounced secretary vacuolation within lobules, as compared to the wild-type mouse. However, it is still unclear whether the abnormal mammary gland of waved-2 mice is due to a developmental problem or to the impaired function of the EGF receptor.

Three groups have generated null mutations of the EGF receptor in mouse by homologous recombination in embryonic stem (ES) cells [23-25]. The phenotype of the null mutation in mouse turned out to be different in different genetic backgrounds. However, no female mice live long enough to develop mature mammary gland. Thus, the null mutation of the EGF receptor in mouse does not provide us with a model to study the role of the EGF receptor in mammary cancer. Therefore, we need to generate a mutant mouse lacking EGF receptor specifically in the mammary gland. Recent success of cre-loxP mediated gene knockout technique [26], which allows one to change the gene of interest in a tissue-specific manner, provides us with the tool to generate mice lacking EGF receptor only in the mammary gland. This mutant mouse will be our model to study the role of the EGF receptor in mammary cancer. We will evaluate the effect of the EGF receptor on the incidence of mammary tumors induced by chemical carcinogenesis. Analysis of this mutant mouse should reveal the role of the EGF receptor in the etiology and progression of breast cancer and will indicate the significance of the EGF receptor as a therapeutic target.

Body

1) Construction of the targeting vector for EGF receptor gene. (Task 1 in statement of work)

The targeting vector was finished last year as show in figure 1.

2) Cloning of the promoter region of WAP (white acid protein) gene and construction of WAP-*cre*. (Task 2 in statement of work)

We have cloned the promoter region of WAP last year and made the construct containing 3.5 kb WAP promoter and *cre* gene. After we made the construct, Jackson Lab has obtained the license from DuPont to sale transgenic mouse containing *cre* gene, including WAP-*cre* mouse, which is the same one that we plan to generate. Therefore, in stead of generating our own strain of mouse, we will purchase WAP-*cre* mouse from Jackson Lab when we need it.

3) Electroporation of ES cells with EGF receptor construct. (Task 3 in statement of work)

We have introduced the EGF receptor targeting vector we constructed into ES cells by electroporation. After ten days of G418 selection, we have isolated about 500 colonies. Each individual clone was expanded and the DNA from each clone is isolated for Southern blot analysis. The probe we used for Southern blot analysis is a ~500 bp fragment 5'-end outside targeting construct. After analyzing more than 400 individual clones, we identified 11 positive ones. We expanded the ES cells from those 11 positive clones for more DNA to confirm those ES cells had gone through the correct DNA recombination. We also use the *neo* gene as well as a 3'-end fragment as probes to determine the correct recombination. Southern bolt analysis reveals several positive ones.

4) Electroporation of ES cells with the *cre* gene to remove the *neo* gene cassette. (Task 3 in statement of work)

One of positive clones was selected to remove the *neo* gene cassette. The ES cells was electroporated with a plasmid containing *cre* gene under the control of CMV promoter. About 20 G418 negative clones were picked up. However, Southern blot analysis revealed that all of them were type II deletion (figure 2), and we expected to get 50% type I deletion and 50% type II deletion. We further tried several times with the same result. After attending the "Mouse Molecular Genetics" meeting, we found out some other labs have the same problem as we have. In order to solve the problem, we took several approaches. We used a different promoter, such as PGK, to express *cre* gene in ES cells and lowered the amount of the *cre* gene construct for eletroporation. After several trials, we were able to resolve the problem. Now we have both type I and type II deletion of ES cells. From the meeting, we have also learned that we do not have to generate both type I and type II deletion for our study

to understand the role of EGF receptor in mammary gland tumor. Recently, many labs have shown transgenic mice containing cre recombinase is sufficient to delete the exon of gene of interest to more than 80%. Apparently, it becomes not necessary for us to generate type II deletion mice for our studies and we will only need to generate type I homozygous mice that carrying two copies of loxP sites flanking exon 1 of EGF receptor. Therefore, it will save a lot of time to generate mice in our studies.

5) Generating mouse containing loxP sites flanking exon 1 of EGF receptor gene. (Task 5 in statement of work)

To generate mouse containing loxP sites flanking exon 1 of EGF receptor, we injected ES cells with type I deletion to generate chimeric mice. Recent studies have shown that transgenic mice carrying a *cre* gene under the control of EIIa promoter are able to delete sequence at the zygote stage [27]. Several other labs have used this strain of mice to delete the *neo* gene cassette successfully. Therefore, we are also going to try it. In other words, we will generate mice with our ES containing the *neo* gene cassette, and then will cross with EIIa-*cre* mouse, which is also available at Jackson Lab, to remove the *neo* gene cassette. We have generated some chimeric mice and are waiting for germ-line transmission.

Conclusions:

This year, we have run into some problems but we have resolved it. At the same time we have found ways to save time for our project from studies of other labs. It appears that we are a little behind our project according to our proposal; however, we will be able to catch up next year since we will save time in generating mice that we are going to use in our studies. We do not have any data related to breast cancer now, but we are moving along with our project. Next year we hope we will have the transgenic mouse to start our studies related to breast cancer.

References

1. Horwitz, K. B., McGuire, W. L., Pearson, O. H., et al. Predicting response to endocrine therapy in human breast cancer: A hypothesis. Science 189:726, 1975.

2. Harris, A. L. What is the biological, prognostic, and therapeutic role of the EGF receptor in human breast cancer? Breast Cancer Res. Treat. 29:1-2, 1994.

3. Foekens, J. A., Portengen, H., van Putten, W. L., Trapman, A. M., Reubi, J-C, Alexieva-figusch, J., and Klijn, J. G. Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer. Cancer Res. 49:7002-7009, 1989.

4. Marcias, A., Azavedo, E., Perez, R., et al. Receptors for epidermal growth factor in human mammary carcinomas and their metastases. Anticancer Res. 6:849, 1986.

5. Toi, M., Tominaga, T., Osaki, A., and Toge. T. Role of epidermal growth factor receptor expression in primary breast cancer: Results of a biochemical study and an immunocytochemical study. Breast Cancer Res. Treat. 29:51-58, 1994.

6. Weidner, N., and Gasparini, G. Determination of epidermal growth factor receptor provides additional prognostic information to measuring tumor angiogenesis in breast carcinoma patients. Breast Cancer Res. Treat. 29:97-108, 1994.

7. Klijn, J-G., Berns, P. M., Schmitz, P. I., and Foekens, J. A. Epidermal growth factor receptor (EGF-R) in clinical breast cancer: Update 1993. Endocr. Rev. Monographs 1:171-174, 1993.

8. Klijn. J-G., Berns, P. M., Schmitz, P. I., and Foekens, J. A. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr. Rev. 13:3-17, 1992.

9. Ullrich, A., Coussens, L., Hayflic, J. S., Dull, T. J., Gray, A., Tam, A. W., Lee. J., Yarden, Y., Libermann, T. A., and Schlessinger, J. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 309:418-425, 1984.

10. Neal, D. E., Benntt, M. K., Hall, R. R., Marsh, C., Abel, P. D., Sainsbury, J. R., and Harris, A. L. Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumors. Lancet I:366-368, 1985.

11. Yasui, W., Hata, J., Yokozaki, H., Nakatani, H., Ochiai, A., Ito, H., and Tahara, E. Interaction between epidermal growth factor and its receptor in progression of human gastric carcinoma. Int. J. Cancer 41:211-217, 1988.

12. Dazzi, H., Hasleton, P. S., Thatcher, N., Barnes, D. M., Wilkes, S., Swindell, R., and Lawson, R. A. Expression of epidermal growth factor receptor (EGF-R) in non-small cell lung cancer. Use of archival tissue and correlation of EGF-R with histology, tumor size, node status and survival. Br. J. Cancer 59:746-749, 1989.

13. Schneider, M., Etienne, M. C., Dassonville, O., Francoual, M., Formento, J. L., Ramaioli, A., Demard, F., and Milano, G. Epidermal growth factor receptor in head and neck carcinoma: prognostic value as compared to the initial stage. Proc. AACR 34:231[abs 1380], 1993.

14. Scambia, G., Benedetti Panici, P., Battaglia, F., Ferrandina, G., Baiocchi, G., Greggi, S., De Vincenzo, R., and Mancuso, S. Significance of epidermal growth factor receptor in advanced ovarian cancer. J. Clin, Oncol. 10:529-535, 1992.

15. Van der Burg, M. E., Henzen-Logmans, S. C., Foekens, J. A., Berns,P. M., Rodenburg, C. J., Van Putten, W. L., and Klijn, J. G. The prognostic value of epidermal growth factor receptors, determined by both immunohistochemistry and ligand binding assays, in primary epithelial ovarian cancer: a pilot study. Eur. J. Cancer 29:1951-1957, 1993.

16. Dickson, R. B., Gottardis, M. M., and Merlino, G. T. Molecular insights into breast cancer from transgenic mouse models. BioEssays 13:591-596, 1991.

17. Matsui, Y., Halter, S. A., Holt, J. T., Hogan, B. L., and Coffey, R. J. Development of mammary hyperplasia and neoplasia in MMTV-TGF alpha transgenic mice. Cell 61:1147-1155, 1990.

18. Jhappan, C., Stahle, C., Harkins, R. N., Fausto, N., Smith, G. H., and Merlino, G. T. TGF alpha overexpression in transgenic mice induces liver neoplasia and abnormal development of the mammary gland and pancreas. Cell 61:1137-1146, 1990.

19. Sandgren, E. P., Luetteke, N. C., Palmiter, R. D., Brinster, R. L., and Lee, D. C. Overexpression of TGF-alpha in transgenic mice: Induction of epithelial hyperplasia, pancreatic metaplasia, and carcinoma of the breast. Cell 61:1121-1135, 1990.

20. Stewart, T. A., Pattengale, P. K., and Leder, P. Spontaneous mammary adenocarcinoma in transgenic mice that carry and express MTV/myc fusion genes. Cell 38:627-637, 1984.

21. Schonenberger, C. A., Andres, A. C., Groner, B., van der Valk, M., LeMeur, M., and Gerlinger, P. Targeted c-myc gene expression in mammary glands of transgenic mice induces mammary tumors with constitutive milk protein gene transcription. EMBO J. 7:169-175, 1988.

22. Fowler, K. J., Walker, F., Alexander, W., Hibbs, M., Nice, E. C., Bohmer, R. M., Mann, G. B., Thumwood, C., Maglitto, R., Danks., J. A., Chetty, R., Burgess, A. T., and Dunn, A. R. A mutation in the epidermal growth factor receptor in waved-2

mice has a profound effect on receptor biochemistry that results in impaired lactation. Proc. Natl. Acad. Sci. USA 92:1465-1469, 1995.

23. Threadgill, D. W., Dlugosz, A. A., Hansen, L. A., Tennenbaum, T., Lichti, U., Yee, D., LaMantia, C., Mourton, T., Herrup, K., Harris, R. C., Barnard, J. A., Yuspa, S. H., Coffey, R. J., and Magnuson, T. Targeted disruption of mouse EGF receptor: Effect of genetic background on mutant phenotype. Science 269:230-234, 1995.

24. Sibilia, M., and Wagner, E. F. Strain-dependent epithelial defect in mice lacking the EGF receptor. Science 269:234-236, 1995.

25. Mlettlnen, P. J., Berger, J. E., Meneses, J., Phung, Y., Pedersen, R. A., Werb, Z., and Derynck, R. Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. Nature 376:337-341, 1995.

26. Barinaga, M. Knockout Mice: Round Two. Science 265:26-28, 1994.

27. Lasko M., Pichel J. G., German JR, Sauer B., Okamoto Y., Lee E., Alt F. W., Westphal H. Efficient in vivo manipulation of mouse genomic sequences at the zygote stage. . Proc. Natl. Acad. Sci. USA 93:5860-5865.

Appendices

Figure 1. EGF receptor gene targeting construct

exon 1   wildtype locus

exon 1   targeting construct

HSV-tk-neo

homologous recombination

HSV-tk-neo   exon 1   mutant locus

exon 1

type I deletion   type II deletion

Figure 2. Strategy to generate genes flanking by loxP sites in ES cells.
Genetic locus, targeting construct and mutant locus as well as two types
of cre-mediated deletions are shown.
The loxP site: ▶ .